CD56(-) extranodal natural killer (NK)/T-cell lymphoma, nasal type presenting as skin ulcers in a white man.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27752533)

Published in JAAD Case Rep on October 08, 2016

Authors

Charles Vainder1, Jonhan Ho1, Steven H Swerdlow2, Oleg E Akilov1

Author Affiliations

1: Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania.
2: Department of Pathology, Division of Hematopathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Articles cited by this

WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood (2008) 3.56

Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol (2011) 3.10

Current management of nasal NK/T-cell lymphoma. Oncology (Williston Park) (2010) 2.19

How I treat NK/T-cell lymphomas. Blood (2013) 1.96

Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol (2004) 1.48

Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer (1995) 1.47

A unique case of adolescent CD56-negative extranodal NK/T-cell lymphoma, nasal type. Pediatr Dev Pathol (2008) 1.46

Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol (2001) 1.24

Extranodal NK/T-cell lymphoma with cutaneous involvement: 'nasal' vs. 'nasal-type' subgroups--a retrospective study of 18 patients. Br J Dermatol (2008) 1.16

Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol (2014) 1.08

Pathogenesis and treatment of extranodal natural killer/T-cell lymphoma. Semin Hematol (2013) 0.98

Classification of cutaneous lymphomas - an update. Histopathology (2010) 0.93

CD56-negative extranodal nasal type of natural killer/T-cell lymphoma with extranasal skin involvement. Leuk Lymphoma (2009) 0.93

Nasal-type extranodal natural killer/T-cell lymphoma presenting with extensive leg ulcers. Clin Exp Dermatol (2009) 0.90

Immunophenotypic characteristics and clinical relevance of CD56+ and CD56- extranodal nasal-type natural killer/T-cell lymphoma. Leuk Lymphoma (2011) 0.84

CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis. Tumour Biol (2015) 0.81

T-cell receptor (TCR) phenotype of nodal Epstein-Barr virus (EBV)-positive cytotoxic T-cell lymphoma (CTL): a clinicopathologic study of 39 cases. Am J Surg Pathol (2015) 0.80

CD56-Negative Extranodal NK/T-Cell Lymphoma, Nasal Type, with Extranasal Cutaneous Involvement. Ann Dermatol (2015) 0.79

Rapidly enlarging nodular plaque on the leg. JAMA Dermatol (2014) 0.78

Evaluation of T- and NK-cell-targeted therapies: is there a role for rituximab prophylaxis? Clin Cancer Res (2009) 0.78